BMS PD-1 immunotherapy nivolumab dubbed 'breakthrough' by FDA
This article was originally published in Scrip
Executive Summary
The FDA has granted the much sought after designation of breakthrough therapy to Bristol-Myers Squibb's experimental PD-1 immune checkpoint inhibitor nivolumab as a treatment for patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant and Seattle Genetics' Adcetris (brentuximab).